Yangtze Optical Fibre and Cable Joint Stock Co(DE:1YO)
€9.950.00 (0.00%)
DE:1YO
Yangtze Optical Fibre and Cable Joint Stock Co stock drug pipeline
€9.95
At close:0.00 (0.00%)
Yangtze Optical Fibre and Cable Joint Stock Co (1YO) Drug Pipeline
2 Followers
This company reports no clinical trials.
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Yangtze Optical Fibre and Cable Joint Stock Co Class H (DE:1YO) have in its pipeline
Yangtze Optical Fibre and Cable Joint Stock Co DE:1YO does not currently report any drugs in clinical development.
